3.11
0.32%
-0.01
After Hours:
3.01
-0.10
-3.22%
Evaxion Biotech A S Adr stock is traded at $3.11, with a volume of 32,559.
It is down -0.32% in the last 24 hours and up +1.97% over the past month.
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.
See More
Previous Close:
$3.12
Open:
$3.11
24h Volume:
32,559
Relative Volume:
0.68
Market Cap:
$17.34M
Revenue:
-
Net Income/Loss:
$-24.47M
P/E Ratio:
-3.1735
EPS:
-0.98
Net Cash Flow:
$-24.56M
1W Performance:
+5.42%
1M Performance:
+1.97%
6M Performance:
-2.81%
1Y Performance:
-62.67%
Evaxion Biotech A S Adr Stock (EVAX) Company Profile
Name
Evaxion Biotech A S Adr
Sector
Industry
Phone
-
Address
-
Evaxion Biotech A S Adr Stock (EVAX) Latest News
European Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading - MSN
Evaxion Biotech A/S ADR (EVAX) Stock: From Low to High in 52 Weeks - The InvestChronicle
EVAX’s price-to-cash ratio: Is it a good investment at the moment? - US Post News
Evaxion Biotech Partners With Merck To Expand Vaccine Development - Benzinga
Evaxion Biotech inks vaccine licensing deal with MSD - Investing.com
Evaxion stock jumps on expanded vaccine development pact with MSD (NASDAQ:EVAX) - Seeking Alpha
H.C. Wainwright keeps buy rating on Evaxion stock, cites promising AI-powered cancer vaccine - Investing.com
Evaxion Biotech enhances AI vaccine discovery platform - Investing.com
Evaxion Biotech enhances AI vaccine discovery platform - Investing.com India
Evaxion launches improved AI-Immunology™ platform for vaccine antigen prediction - GlobeNewswire Inc.
European Equities Traded in the US as American Depositary Receipts Higher in Monday Trading - MSN
Evaxion reports promising phase 2 trial results for cancer vaccine - Investing.com
European Equities Traded in the US as American Depositary Receipts Track Lower in Wednesday Trading - MSN
Evaxion reports high response rate in melanoma trial - Investing.com
Evaxion reports breakthrough in gonorrhea vaccine research - Investing.com
Evaxion obtains pre-clinical Proof-of-Concept for mRNA Gonorrhea vaccine candidate EVX-B2 - GlobeNewswire Inc.
European Equities Traded in the US as American Depositary Receipts Trend Higher in Tuesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Higher in Wednesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Edge Lower Friday; Set to End Week Up 0.5% - MSN
European Equities Traded in the US as American Depositary Receipts Nudge Lower in Monday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading - MSN
Earnings call: Evaxion Biotech reports Q2 results, optimistic on EVX-01 - Investing.com India
Earnings call: Evaxion Biotech reports Q2 results, optimistic on EVX-01 - Investing.com
Earnings call: Evaxion Biotech reports Q2 results, optimistic on EVX-01 - Investing.com UK
Here's Why Evaxion Biotecch (EVAX) Is a Great 'Buy the Bottom' Stock Now - MSN
European Equities Traded in the US as American Depositary Receipts Move Lower in Tuesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Trend Lower Friday; Set to End Week Down 4% - MSN
European Equities Traded in the US as American Depositary Receipts Trend Lower Thursday - MSN
MSN - MSN
CVB Financial Corp secures key executives with new employment agreements By Investing.com - Investing.com India
Cathie Wood's ARK ETF adjusts portfolio with key stock trades on July 8 By Investing.com - Investing.com
Winmill & Co. buys shares of Bexil Investment Trust worth over $12k By Investing.com - Investing.com
Evaxion Biotech reports progress in AI-powered vaccine development By Investing.com - Investing.com UK
European Equities Traded in the US as American Depositary Receipts Lower Tuesday - MSN
European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading - MSN
Evaxion Biotech advances in personalized cancer vaccine - Investing.com India
Evaxion Biotech advances in personalized cancer vaccine By Investing.com - Investing.com India
Evaxion Biotech advances in personalized cancer vaccine By Investing.com - Investing.com
Evaxion Biotech advances in personalized cancer vaccine By Investing.com - Investing.com UK
Evaxion Receives Positive Feedback on Patent Application for AI-Based Novel Cancer Vaccine Target Identification Method - GlobeNewswire Inc.
Evaxion Biotech advances in personalized cancer vaccine - Investing.com
Evaxion (EVAX) Enrolls First Patient in Phase IIb Melanoma Study - Yahoo New Zealand News
European Equities Traded in the US as American Depositary Receipts Nudge Higher Tuesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Trend Lower Friday But End Week Higher - MSN
Bank Stocks Help Nudge European Equities Traded in the US as American Depositary Receipts Higher in Monday Trading - MSN
Stocks of Evaxion Biotech A/S ADR (EVAX) are poised to climb above their peers - SETE News
Daily Progress: Evaxion Biotech A/S ADR (EVAX) Gain 8.10, Closing at 2.67 - The Dwinnex
Evaxion Biotech A/S ADR (EVAX) Stock: Navigating a Year of Stock Volatility - The InvestChronicle
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Tuesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Open Week Slightly Higher in Monday Trading - MSN
Evaxion reports positive results for melanoma vaccine - Investing.com India
Evaxion Biotech A S Adr Stock (EVAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):